Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, 960-1295, Japan.
Department of Multidisciplinary Treatment of Cancer and Regional Medical Support, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan.
Int J Clin Oncol. 2024 Jul;29(7):865-872. doi: 10.1007/s10147-024-02525-z. Epub 2024 Apr 22.
The biomarker-oriented chemo-immunotherapy is useful and promising in the development of new anticancer agents, since the responders can be enriched by selecting patients with biomarkers. Compared to colorectal and lung cancers, the development of biomarker-driven molecular-targeted therapeutics for gastric cancers has been straggled. However, several new biomarkers in gastric cancers have been discovered and clinical trials in enrichment design with certain biomarkers have been conducted. Therefore, there are currently several treatment options to treat gastric cancer patients based on individual biomarker-oriented strategies. In the present review, we describe the useful biomarkers in gastric cancer, with focusing on HER2, PD-L1, and Claudin18.2, in relation to their clinical significance and associated targeted agents.
生物标志物导向的化疗免疫治疗在开发新的抗癌药物方面是有用且有前途的，因为通过选择具有生物标志物的患者，可以富集应答者。与结直肠癌和肺癌相比，胃癌的生物标志物驱动的分子靶向治疗的发展一直较为滞后。然而，已经发现了几种新的胃癌生物标志物，并且已经进行了针对某些生物标志物的富集设计临床试验。因此，目前有几种治疗选择可以根据个体生物标志物导向的策略来治疗胃癌患者。在本综述中，我们描述了胃癌中有用的生物标志物，重点介绍了 HER2、PD-L1 和 Claudin18.2，以及它们的临床意义和相关的靶向药物。
